CD274 and neoplasm: Various biomarkers such as tumor mutational burden (TMB), PD-L1 expression, microsatellite instability (MSI), mismatch repair defects (dMMR), mutations in cancer driver genes, and immunogenetic signatures are widely used in clinical practice (6, 7).